The patent applications concern its proprietary formulation technologies for its products TX12001HR, TX12002HR and TX12003HR. TherapeuticsMD CEO Robert Finizio said, "The submission of these patents marks a new
The FDA approval is based on two randomized trials which showed that Lyrica significantly reduced neuropathic pain associated with spinal cord injury from baseline throughout the duration of
The Olanzapine and Fluoxetine Capsules are the company’s generic equivalent to Symbyax. Lilly USA commercializes Symbyax, which is approved for the acute treatment of treatment-resistant depression and bipolar
Depomed acquired the product in return for potential milestone payments based on the sales of Zipsor and assumption of certain liabilities. Depomed president and CEO Jim Schoeneck said
The comprehensive suite of modules will support the areas of general toxicology, reproductive toxicology, pathology and pharmacy. The project also includes a systems integration component, replacing a legacy
The company said the intermediates will initially be used as active pharmaceutical ingredients in some of its drugs derived from petroleum products, reports Business Standard. The intermediates facility,
Daikyo Seiko, West’s partner, developed these technologies, which are based on a polymeric container, utilizing elastomeric components with Flurotec barrier film, and provided in a sterile, validated, ready-to-fill
Under the collaboration, GSK acquired exclusive rights to research and develop certain vaccine and inhaled product candidates using Liquidia’s proprietary Particle Replication In Non-Wetting Templates (PRINT) technology. The
The patent entitled, Small-Volume Oral Transmucosal Dosage Forms, describes a method of treating pain by administering a small-volume solid tablet containing sufentanil by adhering to the oral mucosa.
The double-masked study treated nine patients with severe dry eye with RGN-259 or vehicle control six times daily over a period of 28 days. RGN-259 met key efficacy
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.